Still pon­der­ing an M&A move, Gilead­'s R&D team out­lines a Q3 line­up of set­backs on 3 pipeline drugs

Hit on one side by slump­ing hep C rev­enue and on the oth­er side by high ex­pec­ta­tions for its pipeline ef­fort, Gilead grim­ly hung on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.